UNSPSC 51342900: Antiviral purines

Antiviral drugs made from a series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases.

UNSPSC 51342900 Antiviral purines is a Class code that does not align with the state and local procurement activity recently tagged under it. The recent opportunities solicited under this code involve naloxone procurement, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription program development — none of which fall within the scope of antiviral purine compounds. The mismatch suggests either miscoding by issuing bodies or that the code is being applied to broader pharmaceutical and medical supply categories in state and local procurement systems. The issuing bodies using this code include county health departments, municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances, indicating participation across health care delivery, emergency response, and pharmacy benefit administration functions.

Geographic activity appears concentrated in Florida and Texas, with multistate reach through the Minnesota Multistate Cooperative Purchasing Alliance serving participating jurisdictions including Oregon. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; the City of Tampa's invitation to bid for medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and a March 13, 2026 deadline; the Texas Health and Human Services Commission's Request for Information regarding direct-to-manufacturer prescription programs posted April 3, 2026; and the Minnesota Department of Administration's RFP through MMCAP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The code shows no clear recent activity in its nominal antiviral purine scope.